Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Grifols, S.A.
The Phase III trial of BT524 produced positive topline results in patients with acquired fibrinogen deficiency, potentially making it the first fibrinogen concentrate to win US FDA approval for that indication.
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
The Phase II trial was not powered to show statistical significance on cognitive efficacy, but early Alzheimer’s patients treated with Araclon/Grifols’ anti-Aβ40 vaccine had slower decline by some measures.
The following four neurological products are likely to reach market next year. Carving out sales will be an entirely different problem.
- Diagnostic Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Alpha Therapeutic Corporation
- Biotest AG
- Goetech LLC
- GigaGen, Inc.
- Grifols Therapeutics, Inc.
- Talecris Biotherapeutics Inc.
- Haema AG.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.